These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22219190)

  • 1. Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase.
    Hall J; Aulabaugh A; Rajamohan F; Liu S; Kaila N; Wan ZK; Ryan M; Magyar R; Qiu X
    J Biol Chem; 2012 Mar; 287(10):7717-27. PubMed ID: 22219190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syk kinase as a treatment target for therapy in autoimmune diseases.
    Kyttaris VC; Tsokos GC
    Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Involvement of Syk in pathology of systemic autoimmune disease].
    Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Syk inhibitors].
    Kimura Y; Chihara K; Takeuchi K; Sada K
    Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.
    Narula SS; Yuan RW; Adams SE; Green OM; Green J; Philips TB; Zydowsky LD; Botfield MC; Hatada M; Laird ER
    Structure; 1995 Oct; 3(10):1061-73. PubMed ID: 8590001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly potent aminopyridines as Syk kinase inhibitors.
    Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol.
    Kaur M; Kumari A; Bahia MS; Silakari O
    J Mol Graph Model; 2013 Feb; 39():165-75. PubMed ID: 23280414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and biophysical characterization of the Syk activation switch.
    Grädler U; Schwarz D; Dresing V; Musil D; Bomke J; Frech M; Greiner H; Jäkel S; Rysiok T; Müller-Pompalla D; Wegener A
    J Mol Biol; 2013 Jan; 425(2):309-33. PubMed ID: 23154170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role of water molecules for docking and receptor guided 3D-QSAR analysis of naphthyridine derivatives as spleen tyrosine kinase (Syk) inhibitors.
    Kaur M; Bahia MS; Silakari O
    J Chem Inf Model; 2012 Oct; 52(10):2619-30. PubMed ID: 22900966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.
    Pamuk ON; Tsokos GC
    Arthritis Res Ther; 2010; 12(6):222. PubMed ID: 21211067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
    Li M; Luraghi P; Amour A; Qian XD; Carter PS; Clark CJ; Deakin A; Denyer J; Hobbs CI; Surby M; Patel VK; Schaefer EM
    Anal Biochem; 2009 Jan; 384(1):56-67. PubMed ID: 18762159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.
    van Bree SH; Gomez-Pinilla PJ; van de Bovenkamp FS; Di Giovangiulio M; Farro G; Nemethova A; Cailotto C; de Jonge WJ; Lee K; Ramirez-Molina C; Lugo D; Skynner MJ; Boeckxstaens GE; Matteoli G
    Gut; 2013 Nov; 62(11):1581-90. PubMed ID: 23242119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.